Among females worldwide, cervical cancer (CC) was the third most common malignant cancer and the fourth leading cause of cancer death, accounting for 9% (529,800) of new female cancer cases and 8% of female deaths in 2008 1
, to establish miRNA-based tumor biomarker. Furthermore, studies have demonstrated that miRNAs are stably maintained in a variety of biological fluids, including human serum/plasma, urine, breast milk, tears, bronchial lavage, colostrum, seminal, amniotic, pleural, peritoneal and cerebrospinal fluids. The species and quantities of circulating miRNAs reflect the physiological and pathological conditions of the human body. These findings suggested that the circulating miRNAs can be candidates for blood-based biomarker for cancer diagnosis [12] [13] [14] [15] [16] and prognosis [17] [18] [19] [20] . However, the value of circulating miRNAs in diagnosis of CC has yet to be determined.
In this study, we studied serum samples from a large cohort of CC patients, cervical intraepithelial neoplasia (CIN) individuals and healthy control subjects (HC). After step-wise screening and validation, we established a 4-miRNA signature for early CC detection. Moreover, we investigated the tumorigenic roles of a representative miRNA in vitro and in a tumor implantation mouse model.
Materials and Methods
Clinical Cohorts. The patient cohort was composed with 184 CC, 20 breast cancer, and 20 ovarian cancer patients. These patients were diagnosed at different stage of cancer in Peking Union Medical College Hospital (PUMCH) between July 2012 and June 2013 (Table 1) . Venous blood samples were collected from patients prior to any surgery or chemoradiotherapy treatment. 186 CIN individuals (Table 1) and 213 healthy subjects were also recruited to establish control groups. All the cancer and CIN patients were confirmed according to their histopathological examination results. Written informed consent was obtained from each of the participant and the study was approved by the institutional review board of PUMCH. The study was conducted in accordance with the principles of the Declaration of Helsinki, the standards of Good Clinical Practice (as defined by the International Conference on Harmonization).
Study procedures.
Step-by-step biomarker discovery procedure includes three phases -full screening phase, training phase, and, validation phase. Human subjects were randomized for selection into different phase of studies. The miRNA candidates in each phase were determined based on the profiling results of prior phase of study and a logistic model, which aims to discriminate CC, CIN and healthy subjects.
Phase #1, full screening phase. Serums from four female CC patients as well as five age-matched healthy female were collected. Expression profiles of 444 miRNAs were determined among these 2 groups. Candidate miRNAs for phase #2 were determined to be miRNAs with > 2 fold changes of abundance and p < 0.05 with False Discovery Rate (FDR) adjustment.
Phase #2, training phase. The 66 miRNA candidates identified in phase #1 were tested in the serum samples from independent cohorts of 95 CC, 95 CIN, and 95 healthy female subjects. Candidate miRNAs for phase #3 were determined to be miRNAs with p < 0.05 in Mann-Whitney U test.
Phase #3, validation phase. Seven candidate miRNAs from phase #2 was further validated in independent cohorts of serum samples including 85 CC, 91 CIN, and 93 healthy subjects. All above CC patients (184 cases) and health controls (193 subjects), as well as 186 cases of CIN patients were used to construct the diagnostic microRNA panel Data analysis. Serum miRNA levels among different groups of subjects were normalized by exogenous control:
cel-miR-67, and analyzed by Real Time StatMiner (Integromics). miRNAs with differential expression (based on 2 -△△Ct method) were sorted out by Mann-Whitney U test with False Discovery Rate (FDR) adjustment for further analysis. Mann-Whitney U test with bonferroni adjustment was used to compare the microRNAs expression level between different groups. Receiver-operating characteristic (ROC) curves and the area under the ROC curve (AUC) were used to evaluate the sensitivity and specificity of miRNA biomarkers for the diagnosis of CC. Statistical evaluations were performed using the Statistical Package for the Social Sciences (SPSS 13.0) and graphs were generated using GraphPad Prism 5.0 (GraphPad Software). P-values of < 0.05 were considered statistically significant.
Cell culture and transfection. One DNA fragment containing hsa-mir-497 was constructed to lentiviral vector, pUGWT (Addgene). The transfection of the plasmid was performed with LTX and PLUS reagents (Invitrogen) into HEK 293T, as previously described 21 . Viruses were harvested 48 h after transfection and used to infect Hela cells. Flow cytometry was used to determine the efficiency of infection in 48 h after the infection and cells stably expressing hsa-mir-497 were harvested for further analysis.
MTT assay. The MTT method was used to estimate cell viability. Hela cells were seeded at an initial density at 2000 cells/wellin flat-bottom, 96-well cell culture plate and allowed to grow for 24 h at 37 °C 5% CO 2 . 20 μ L MTT (BIO-BOX) solutions were added to each well followed by additional 4 h incubation. After removing the media, 150 μ L dimethyl sulfoxide was added to each well to solubilize the formazan crystals. After 30 min stirring at room temperature (RT), the plates were scanned spectrophotometrically with a microplate reader at 490 nm for measuring the absorbance.
Cell Apoptosis Assay. Apoptosis and cell death were detected using the Caspase-Glo Apoptosis Detection Kit according to manufactures' instructions (Invitrogen), Briefly, Hela cells were seeded in 96-well plates at 10000 cells per well and incubate for 24 h at 37 °C, 5% CO 2 . Then, the medium was removed and washed with PBS, and followed with an additional incubation for 48 h in the presence of FBS-free medium. 100 μ l of Caspase-Glo ® 3/7
Reagent was added to each well and incubated for 30 min at RT. Luminescence of each sample was subsequently measured in a plate-reading luminometer (EnVision 2100Multilabel Reader, PerkinElmer).
Animal studies. Female BALB/C nude mice of 6-8 weeks old (Vital River Laboratories, VRL, Beijing, China) were housed within a dedicated SPF facility at Laboratory Animal Center of PUMCH. Stable Hela cells with over-expressing miR-497 or blank controls were harvested, and injected into right-side flank of mice subcutaneously at a concentration of 4 × 10 7 cells/ml in PBS (100 μ l/mouse).The mice were monitored after injection and tumors were measured every two days with a vernier caliper. All mice were killed on day 30 after injection and subcutaneous tumors were surgically excised, weighed, photographed, sectioned, and stained with haematoxylin-eosin. Animal experiments were approved by PUMCH animal ethics committee and the methods were carried out in accordance with the approved guidelines.
Results
Stepwise selection procedure to identify a circulating miRNA panel in CC patients. To identify differential circulating miRNA profiles in blood of CC patients, four CC patients and five age-matched controls were enrolled for full screening. As shown in Fig. 1 , with a pool of 444 human miRNAs, circulating miRNAs within serum samples were quantified by qRT-PCR. We used three parameters for the phase #2 candidates selection: (1) Ct values < 30; (2) p < 0.05 in Mann-Whitney U test; and (3) difference of miRNA levels > 2 folds. In comparison to the control group, we identified that 66 circulating miRNAs were significantly different in CC patients (p < 0.05), of which 32 were downregulated and 34 were upregulated (Supplemental Table 1 ). We next evaluated these putative 66 candidate miRNAs in the training phase, which included samples from 95 CC patients, 95 CIN patients and 95 healthy controls. Seven miRNAs (miR-497, miR-371a-5p, miR-16-2*, miR-195, miR-2861, miR-499-3p and miR-602) remains distinct in the CC patient group (Supplemental Table 2 ). We further validated these 7 miRNAs in the validation phase, which consisted of an independent cohort of 85 CC patients, 91 CIN patients and 93 healthy controls. After this final validation step, three miRNAs were eliminated and the rest 4 miRNAs, miR-497, miR-16-2*, miR-195 and miR-2861, were determined to be a specific circulating miRNA signature in CC patients (Supplemental Table 2 ).
A 4-miRNA panel signature discriminate CC patients from CIN and healthy subjects.
Retrospectively, we evaluated the levels of these four miRNAs in combined cohorts, which include 184 CC, 186 CIN and 193 control individuals enrolled in all screening stages. Across these three experimental groups, there is no statistical difference for the level of circulating miR-16-2*, miR-195 and miR-497 between healthy control and CIN subjects, but miR-195 is significantly decreased while miR-16-2* and miR-497 is significantly increased in the blood of CC patients in comparison to the prior two groups ( Fig. 2A-C) ; in comparison to the healthy control group, miR-2861 is significantly decreased in CIN and CC patients (Fig. 2D) . We next compared of these four miRNAs levels between different stages in the CC patients, but no significance difference was found among stage I-III (supplementary Figure 1) .
Furthermore, with ROC analysis, we evaluated diagnostic values of this 4-miRNA in distinguishing CC patients from CIN and health control subjects. A stepwise logistic regression model for CC prediction was applied on the all data set. The prediction value was significant for each single miRNAs (Fig. 2E-G, Table 2 ). When miR-497, miR-16-2*, miR-195 and miR-2861 were combined together to form a panel, it showed a high accuracy in discriminating CC from healthy controls (AUC: 0.849; 95% CI: 0.813-0.886; sensitivity: 73.1%, specificity: 88.4%) and from CIN (AUC: 0.829; 95% CI: 0.794-0.865; sensitivity: 71.4%, specificity: 67.2%), as well as CIN from healthy controls (AUC: 0.734; 95% CI, 0.683-0.784; sensitivity: 62.6%, specificity: 88.9%) (Fig. 2E-G The specificity for cervical cancer of 4-miRNA panel. To verify the diagnostic power of this 4-miRNA panel, we further assessed its specificity in prediction with other common female cancers. We recruited independent cohorts including 20 breast cancer patients, 20 ovarian cancer patients and 20 healthy control subjects and quantified levels of these four circulating miRNAs with their serum samples. Similar to that of CC, comparing to HC subjects, the level of miR-16-2* was also elevated in serum samples from breast cancer and ovarian cancer patients. While there is no significant difference between breast cancer and HC groups, opposite to that of CC, miR-2861 and miR-195 increased in serum of ovarian cancer patients. Also, levels of miR-497 were not changed across all three groups examined (Fig. 3A-D) .
miR-497 as a tumor suppressor for cervical cancer.
Previous studies from others demonstrated that miR-497 played important roles in tumor suppression in human cervical cancer 22 . However, in our current study, we found that miR-497 is significantly increased in CC patients in comparison to the healthy control and CIN group. We speculated either miR-497 plays different role in cervical tumorigenesis, or, tumor cells were not major contributor for the elevation of circulating miR-497. To examine these possibilities, we studied the functional roles of miR-497 during CC development both in vitro and in vivo.
To explore the potential role of miR-497 in CC development, CC originated Hela cells were transfected with miR-497 and subsequently confirmed by GFP flow cytometry analysis 48 h post transfection. First, we demonstrated that caspase-3/7 activity was significantly increased in miR-497 over-expressing cells compared with mock transfected Hela cells (Fig. 4A ). Comparing to GFP expressing control, miR-497 significantly inhibited the growth of Hela cells (Fig. 4B) . These data indicated that miR-497 could promote apoptosis and inhibit proliferation of Hela cells.
miR-497 and GFP tranfected Hela cells were injected subcutaneously into two groups of 6-to 8-week old female BALB/C nude mice respectively. Tumors were collected and weighted 30 days after injection. As shown in Fig. 4 , both tumor volume and tumor weight were significantly reduced in mouse injected with Hela cells over-expressing miR-497. Moreover, the formation of tumors was also significantly delayed when miR-497 was forced to express in Hela cells (Fig. 4C-F) . These results indicated that miR-497 would suppress CC tumor growth.
Therefore, we suspected that the elevation of circulating miR-497 was not contributed by cervical tumor cells. , and CC and HC subjects (G) were demonstrated accordingly by regression analysis. The value of area under curve (AUC) was showed following each miRNA and a 4 miRs panel. CC, cervical cancer; CIN, cervical intraepithelial neoplasia; HC, healthy subjects. P values were calculated using the Mann-Whitney test. ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001.
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Discussion
Due to the stability and presence in almost all body fluids, miRNAs were considered to be a novel class of non-invasive biomarkers. Numerous studies have explored the application of miRNAs as diagnosis or prognosis markers in a variety of diseases [8] [9] [10] [11] [23] [24] [25] . In this study, we comprehensively evaluated the content of circulating miRNAs in a large cohort of CC patients. The circulating miRNA signature identified in serum of CC patients is the first set of such miRNA panel (miR-497, miR-16-2*, miR-195 and miR-2861) that can distinguish cervical cancer from CIN patients and healthy control with high sensitivity and specificity. Therefore, we propose to establish this panel as a novel noninvasive biomarkers for early detection of cervical cancer. The efficacy of this panel in early diagnosis will be examined in a larger cohort.
In this study, we recruited not only cervical cancer and healthy controls but also CIN individuals. Due to the stepwise progression of CC, these 4 miRNAs could be mis-regulated in tumor and mis-presented in serum at any specific tumorigenesis stage. An ideal diagnosis panel should be able to not only distinguish CIN patients from the late stage malignancy, but also to call out CIN case in the mass of healthy subjects. This goal has been achieved with this 4-miRNA panel. It distinguishes CIN from HC group with 88.9% specificity and CC from CIN group with 67.2% specificity. MiR-195 as a tumor suppressor was found decreased in various cancers and functioned in multiple pathways. It has been reported that MicroRNA-195 suppressed angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2, and CDC42 26 and inhibited non-small cell lung cancer cell proliferation, migration and invasion by targeting MYB 27 . In prostate carcinoma, miR-195 suppressed tumor cell proliferation and metastasis by directly targeting BCOX1 28 . In colorectal cancer, MicroRNA-195 inhibits colorectal cancer cell proliferation, colony-formation and invasion through targeting CARMA3 29 . MiR-16 was reported clustered to miR15 either as tumor suppressor in acute promyelocytic leukemia 30, 31 and osteosarcoma 32 or an oncogene in melanoma 33 and in the plasma of colorectal cancer 34 . Recently a miR-15b/16-2 knockout mice model showed that miR-15b/16-2 could modulate the CCND2, CCND1, and IGF1R genes involved in proliferation and antiapoptotic pathways in mouse B cells 35 . The study of miR-2861 is limited and it has been reported that miR-2861 was up-regulated in papillary thyroid carcinoma with lymph node metastasis 36 . In this study, we determined that miR-16-2* is up-regulated in sera of CC patients, while miR-195 and miR-2861 were decreased. Further studies are needed to explore the potencial mechanism of these three miRNAs on CC development. The down-regulation of miR-497 has a general tumor-promoting effect in multiple cancers and miR-497 was deemed to be a tumor suppressor 22, 37 . For instance, in HCC patients, the inhibition of miR-497 correlated with the up-regulation of CHEK1 38 and multiple cell-cycle regulators, such as CCNE1, CDC25A and CDK4 39 . In non-small cell lung cancer, downregulation of miR-497 promotes tumor growth and angiogenesis by targeting HDGF 40 . miR-497 suppresses proliferation and induces apoptosis in prostate cancer cells and breast cancer cells by targeting Bcl-w 41, 42 . Moreover, Luo M, et al. have found that miR-497 could be a potential prognostic marker and function as a tumor suppressor in human cervical cancer tissues by post-transcriptionally targeting IGF-1R 22 . However, in our data, miR-497 is highly elevated in sera collected from CC patients. We speculated either miR-497 plays different role in cervical tumorigenesis, or, tumor cells were not major contributor for the elevation of circulating miR-497. To examine these possibilities, CC originated Hela cells were transfected with miR-497 and its impact on tumor cell growth were assessed. We found that miR-497 indeed promotes apoptosis and inhibits proliferation of Hela cells in vitro. Moreover, in xenotransplant model, we also found tumor volume and weight were significantly reduced with miR-497 transfected Hela cells. These results indicated that miR-497 played important roles in CC cell apoptosis and viability, and would suppress CC tumor growth, which was consistent with previous findings 22 . Therefore, we suspected that the elevation of circulating miR-497 was not contributed by cervical tumor cells.
In conclusion, we have established a serum miRNAs panel (miR-16-2*, miR-195, miR-2861, miR-497) that could distinguish CC from CIN and healthy controls with high accuracy. These findings indicated that, as a novel noninvasive biomarker, circulating miRNAs would provide considerable diagnostic values in screening cervical cancer.
